NVS — Novartis AG
Healthcare · ETF XLV · as of 2026-09-18
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Novartis AG
NYQ
Healthcare · Drug Manufacturers - General
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Price & today
$140.37
ATR(14) 3.77 (2.69%)
| Stock today | -0.39% |
| Sector ETF today | -0.25% |
| Residual (stock-specific) | -0.14% |
Sector correlation
| 20-day correlation with XLV | 0.82 |
| 60-day correlation with XLV | 0.66 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $142.39 |
| 20 EMA | $146.42 |
| 50 EMA | $150.41 |
| EMA stack | BEARISH |
| RSI(14) | 37.8 |
| 52-week high distance | -17.65% |
| 52-week low distance | +33.77% |
Signals
| Market F&G | 46.9 |
| Bull% | 12.2% |
| OVTLYR status | SELL (6d) |
| Sector rank | #134 |
| Next earnings | 2026-10-27 (TNS, 37d) |
MarketSmith metrics - our compute
RS Rating
15.3
ADR%
1.5
RMV (tight)
3.0
Ext (ATR>20EMA)
-1.6
Rel Vol
113.0%
U/D 50d
0.79
U/D 25d
0.80
Accum/Dist 25d
5 / 4
EPS YoY
-0.0%
LoD dist
20.0
Off 52w High
17.7%
Above 52w Low
15.5%
1W / 1M
+2.3 / -12.4
Avg $Vol 50d
299.0M
Mkt Cap (B)
267.8
Trend 8/8
no
Leads Group
no
Sector XLV
+1.8% 1W
Base len (VCP)
24wk (8/25)
Coil (base shape)
85TVPX
not available: revenue(no EDGAR qtrs=1 fact)
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
20.1
Fwd P/E
14.3
PEG
2.6
Price/Book
6.0
Profit margin
23.9%
ROE
34.9%
Debt/Equity
120.7
Rev growth
-0.7%
Analyst target
$154 (+10%)
Analyst rating
HOLD
Institutional %
7.1%
Insider %
0.0%
Float %
95.2%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
4 / 147
Industry
Drug Manufacturers - General
Float
1.82B
Float turnover 20d
0.1%
Avg $Vol 20d / 50d
362.4M / 299.0M
Days to cover
3.5
Short % float
0.3%
Institutional %
7.1%
Weinstein stage
1
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Oct-24 | 2.06 | +18% | - | - |
| Jan-25 | 1.98 | +29% | - | - |
| Apr-25 | 2.28 | +27% | - | - |
| Jul-25 | 2.42 | +23% | 14,836.0 | - |
| Oct-25 | 2.25 | +9% | 14,358.0 | - |
| Feb-26 | 2.03 | +3% | 13,860.0 | - |
| Apr-26 | 1.65 | -28% | 13,524.0 | - |
| Jul-26 | 2.41 | +0% | 14,951.0 | +1% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 18 + Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR) GlobeNewswire Inc.
- Sep 17 + Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape GlobeNewswire Inc.
- Sep 16 · Is Invesco S&P International Developed Quality ETF (IDHQ) a Strong ETF Right Now? Zacks Investment Research
- Sep 16 + CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand GlobeNewswire Inc.
- Sep 16 + CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient Access GlobeNewswire Inc.
- Sep 15 · World’s largest vision award goes to Botond Roska and José-Alain Sahel GlobeNewswire Inc.
- Sep 15 + 4 Prostate Cancer Drug Stocks to Watch During Awareness Month Zacks Investment Research
- Sep 15 + Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities GlobeNewswire Inc.